Pictet Asset Management Ltd. Sells 1,200 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Pictet Asset Management Ltd. lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.7% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 166,315 shares of the company’s stock after selling 1,200 shares during the period. Pictet Asset Management Ltd. owned approximately 0.19% of IDEXX Laboratories worth $45,792,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of IDXX. Bigelow Investment Advisors LLC raised its position in shares of IDEXX Laboratories by 2.8% in the 2nd quarter. Bigelow Investment Advisors LLC now owns 1,363 shares of the company’s stock valued at $375,000 after buying an additional 37 shares in the last quarter. Ropes Wealth Advisors LLC increased its position in IDEXX Laboratories by 0.5% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 7,293 shares of the company’s stock worth $2,008,000 after purchasing an additional 38 shares in the last quarter. Nordea Investment Management AB increased its position in IDEXX Laboratories by 0.9% during the 1st quarter. Nordea Investment Management AB now owns 4,485 shares of the company’s stock worth $1,003,000 after purchasing an additional 40 shares in the last quarter. Western Wealth Management LLC increased its position in IDEXX Laboratories by 0.7% during the 2nd quarter. Western Wealth Management LLC now owns 5,669 shares of the company’s stock worth $1,562,000 after purchasing an additional 40 shares in the last quarter. Finally, US Bancorp DE increased its position in IDEXX Laboratories by 0.4% during the 1st quarter. US Bancorp DE now owns 12,253 shares of the company’s stock worth $2,739,000 after purchasing an additional 48 shares in the last quarter. 87.04% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently issued reports on IDXX shares. Credit Suisse Group upped their price objective on shares of IDEXX Laboratories from $282.00 to $293.00 and gave the stock an “outperform” rating in a research report on Friday, August 16th. Guggenheim started coverage on shares of IDEXX Laboratories in a research report on Thursday, May 23rd. They set a “buy” rating and a $276.00 price objective for the company. Stifel Nicolaus upped their price objective on shares of IDEXX Laboratories from $255.00 to $295.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. BidaskClub cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a research report on Monday. They set a “neutral” rating and a $277.00 price objective for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. IDEXX Laboratories has an average rating of “Buy” and a consensus price target of $285.29.



In other news, Chairman Jonathan W. Ayers sold 20,000 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.26, for a total value of $5,245,200.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Rebecca M. Henderson sold 4,000 shares of the stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $271.17, for a total transaction of $1,084,680.00. Following the transaction, the director now directly owns 14,696 shares in the company, valued at $3,985,114.32. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 73,305 shares of company stock worth $19,402,442. Insiders own 2.70% of the company’s stock.

NASDAQ IDXX traded up $0.65 on Thursday, hitting $271.64. The company’s stock had a trading volume of 172,247 shares, compared to its average volume of 453,982. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 4.49. IDEXX Laboratories, Inc. has a 1-year low of $176.11 and a 1-year high of $292.17. The company’s 50-day moving average is $279.08 and its 200 day moving average is $252.99. The firm has a market cap of $23.43 billion, a PE ratio of 63.77 and a beta of 0.85.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, August 1st. The company reported $1.43 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.37 by $0.06. IDEXX Laboratories had a net margin of 17.78% and a return on equity of 765.45%. The firm had revenue of $620.10 million during the quarter, compared to analysts’ expectations of $627.10 million. During the same period in the prior year, the company posted $1.23 EPS. The company’s revenue was up 6.8% on a year-over-year basis. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 4.86 EPS for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Read More: Asset Allocation and Your Retirement

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.